Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2024年9月8日
	新闻
	Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1 ... EurekAlert! ... lung cancer. ... The results were presented today at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung ... 标记为不相关
	J&J bolsters Rybrevant-Lazcluze's case against AZ's Tagrisso with survival analysis Fierce Pharma ... lung cancer (NSCLC), according to results presented at the 2024 World Conference on Lung Cancer. Patients who took Tagrisso lived a median 37.3 ... 标记为不相关
	Lower-Risk MDS Population Has Enduring RBC-TI Following Imetelstat Therapy Cancer Network The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing. Presented at: 2024 IASLC World Conference ... 标记为不相关
	Risk Adjusted Net Present Value: What is the current valuation of SpringWorks ... Pharmaceutical Technology ... lung cancer, low-grade glioma, colorectal cancer, ovarian cancer, endometrial cancer, thyroid cancer, melanoma, pancreatic cancer, Langerhans cell ... 标记为不相关
	Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant ... KWKT - FOX 44 ... Lung Cancer (WCLC). This marks ivonescimab's third oral presentation at ... carcinoma, and colorectal cancer, through both monotherapy and combination ... 标记为不相关
	Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49 ... Business Wire ... Lung Cancer's (IASLC) 2024 World Conference on Lung Cancer (WCLC 2024) in San Diego, California. "HARMONi-2 clearly demonstrates that ivonescimab ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈